Mihir Jain: Can Gene Therapy Transform Hemophilia Care in India?
Mihir Jain, MBBS graduate from Government Medical College and Hospital (GMCH), Chandigarh, shared a post on LinkedIn:
“Can gene therapy transform hemophilia care in India?
I recently completed an independent healthcare strategy project exploring the commercial and market access landscape for hemophilia gene therapy in India.
The project combines my medical background with data-driven analysis to evaluate:
- Market opportunity
- Patient population and treatment landscape
- Access and reimbursement challenges
- Competitive environment
- Strategic considerations for commercialization
The project includes:
As an MBBS graduate, I’m building a portfolio at the intersection of healthcare consulting, life sciences strategy, medical affairs, pharmacovigilance, and data analytics by tackling real-world industry questions.
I welcome feedback and would be glad to connect with professionals working in healthcare consulting, pharma, biotech, and life sciences.”
Stay updated with Hemostasis Today.
-
Oct 20, 2026, 06:45Grant Garcia: Why Does a Blood Clot Diagnosis Immediately End an Athlete’s Season?
-
Oct 20, 2026, 06:35Parag Tamhankar: Landmark Study Reveals Genetic Spectrum and Targeted Therapies for ALPS in the Indian Population
-
Oct 20, 2026, 06:26Nina Houben: Neonatal Blood Transfusion Symposium and PhD Defense
-
Oct 20, 2026, 05:46Jan T. Kielstein: DNP Poisoning and Hemoadsorption The Limits of Rescue Therapy
-
Oct 20, 2026, 05:33Giulia Di Paolo: Connecting Plasma Donation to the Patients Who Depend on It
-
Oct 20, 2026, 05:20James Knowles: Exploring Plasma Manufacturing and Strengthening Industry Collaboration
-
Oct 20, 2026, 05:11Giuseppe Lippi։ Understanding Liver Test Abnormalities After AAV Gene Therapy
-
Oct 20, 2026, 05:02Sanam Loghavi: Test Your Hematology Knowledge at ASH 2026!
-
Oct 20, 2026, 04:13Ifeanyichukwu Ifechidere: DOACs Are Not the Answer to Every Anticoagulation Question